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A novel non-mineral oil-based adjuvant. 
II. Efficacy of a synthetic 
sulfolipopolysaccharide in a 
squalane-in-water emulsion in pigs 
L A Th  Hdgers  *~,  P L I P la tenburg  ~, A Lu l t jens  ~;, B Groenve ld  ~, 
T Daze l le  ~ and  M W Wests t ra te  ~
The adjuvanttctty of a sulfohpopolysaccharMe (SLP) mcorporated mto a squalane-m- 
water emulslon (SLP/S/W) was compared wtth that of a mmeral od-m-water (0 /W)  
adjuvant currently used m commerctal porcme vaccmes Groups of pigs were zmmuntzed 
twwe wtth racemes comprtsmg etther macttvated influenza virus (tFlu3 contammg strams 
A/ Swme, MRC-11 and X-79), macttvated pseudorabtes vtrus (tPR V), hve pseudorabtes 
virus ( PR V) or macttvated porcme parvovtrus ( tPP V) as anttgen and SLP / S/ W or O~ W 
as adjuvant Antzbody tltres m serum 2 or 3 weeks after the second tmmumzatton were 
measured by haemagglutmatton mhtbttton (HI) or serum neutrahzatton (SN) assays 
Both adJuvants tgmficantly augmented the anttbody responses agamst he antigens tested 
Mean factors of increase obtamed by SLP /S /W and O~ W were 315 and 91, respecttvely, 
for A/Swme, 478 and 137for MRC-11, 362 and 128for )(-79, 69 and 49for tPRV, and 
23 and 7 for hve PR V Increased humoral tmmuntty agamst hve PR V was affirmed by 
reduced levels and duration of vwus excreted by ptgs after challenge with vtrulent PR V 
Immumzatton ofpigs wtth tPPV plus adjuvant SLP/ S/ W gave 36-fold htgher tttres than 
with O~ W It was concluded that SLP /S /W is more effecttve than O~ W m stlmulatmg 
humoral tmmumty against he vtral anttgens exammed and that the two constttuents SLP 
and S~ W interact synergtsttcally Advantages of SLP /S /W over O/W include stronger 
adjuvantlctty, better blocompatzbdtty and lower doses of actzve substances 
Keyworfls Adjuvant, sulfohpopolysaccharlde, efficacy, pigs, synthetic polymer, squalane-in-water emulsion, lmmuno- 
stimulation, viral vaccines 
The most common types of adjuvants used in vaccines 
for domestic food animals are still emulsions of either 
the oil-in-water or water-in-oil type, based on oll of 
mineral origin In general, these adjuvants exhibit strong 
activity with a wide range of antigens but, possibly owing 
to limited biodegradability and bIocompatlbihty, their 
application is often accompanied with certain side-effects 
and risks Parenteral administration of mineral oll 
emulsions into animals frequently provokes reactions at 
the site of injection of which the severity and duration 
depend on the nature and concentration of the od and 
physlcochemlcal characteristics of the emulsions 1 Studies 
on the kinetics of mineral oil emulsions in vtvo 
demonstrated that considerable quantities of oll remained 
*Solvay SA, Research and Technology, Central Laboratory, 
Apphed Immunology, Rue de Ransbeek 310, 1120 Brussels, 
Belgium *Erasmus Umvers~ty of Rotterdam, Department of 
Immunology, Rotterdam, The Netherlands tSolvay Duphar 
BV, Ammal Health Diws~on, Biological Development Group, 
Weesp, The Netherlands °°To whom correspondence should 
be addressed (Recefved 10 March 1993, rewsed 5 October 
1993, accepted 11 October 1993) 
at the site of injection 2'3 and in other anatomic 
compartments 4 for a long period of time As a 
consequence of this persistence, It cannot be excluded 
that consumers of food of animal origin are exposed to 
oil residues and although detrimental effects of such 
residues are not exhaustively documented, they might 
introduce certain risks to human health In addition, there 
exist also risks to veterinary surgeons or animal handlers 
of accidental autolnjectlon For these reasons, replace- 
ment of the mineral oll components while retaining 
adjuvantlclty but reducing risks is very desirable Several 
attempts have been described and a few veterinary 
vaccines are at present on the market supplemented with 
novel adjuvants e g vitamin E, polyacrylate resins 
(Carbopol, of B F Goodrich), acetylated polymannose 
(Acemannan, Carrlngton Labs) and avndlne Emulsions 
of oils of vegetable origin such as peanut, olive, sesame oil 
etc 5-a or of animal origin, e g squalane and squalene 9,
have also been investigated but activity was almost 
always insufficient compared to mineral oll 
In an accompanying paper 1° we have described the 
adjuvantlclty of a synthetic, high-molecular-weight 
polysucrose derlvatized with fatty acid esters and sulfate 
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groups and Incorporated in a squalane-ln-water emulsion 
towards various protelnlC and viral antigens in laboratory 
animals Effects of this adjuvant formulation on immune 
responses against a number of porcine vtral antigens m 
the target animal species are reported here 
MATERIALS  AND METHODS 
Animals 
Pigs of 8-10 weeks of age were screened for the 
presence of antibodies agamst the viral antigens in 
question and animals with detectable antibody tltres were 
excluded 
Vaccines 
Antigens were prepared as described previously ~° The 
following doses of antigen (corresponding to 1 ml of 
antigen solution) were injected 4 4 #g influenza virus 
A /Swine+40#g MRC-11+20#g X-79 (1Flu3), 108 
TCIDso inactivated pseudorables virus (IPRV), 10 s 
TCIDso live pseudorables virus (PRV), and 105 TCIDso 
macttvated porcine parvovlrus (1PPV) Adjuvants tested 
have been described elsewhere ~° Vaccines were obtained 
by either mixing 1 volume of anttgen with 1 volume 
adjuvant solution or resuspending lyophlhzed virus (live 
PRV) in distilled water or adjuvant solution diluted with 
an equal volume of distilled water 
Vaccination 
Groups of at least five pigs were injected twice 
intramuscularly (i m ) with 2 0 ml vaccine per animal at 
weeks 0 and 3 and blood was collected 2 or 3 weeks after 
the second Immunization 
Antibody titres against influenza and pseudorabies virus 
Anti-influenza and antt-pseudorables virus antibody 
tltres were measured as described previously ~° 
Antibody titres against PPV 
Serum samples were inactivated by mcubatlng for 30 
mln at 56°C and pretreated with 3 volumes of kaolin 
suspension ( ICN/Flow Labs, Irvlne, UK) and twice with 
1 volume of a suspension of 50% gumea-pig red blood 
cells (GpRBC) in PBS Then, 50/4 of the serum samples 
were diluted m PBS in 96-well plates and 50 #1 of a vtrus 
suspension containing 8 HA PPV were added to the 
serum dtlutions After incubation for 45 mln at room 
temperature, 50 #1 of a 0 6% GpRBC suspension in PBS 
were added After 1-2 h, agglutination was detected and 
the reciprocal value of the htghest serum dilution 
demonstrating HI was considered to be the tltre 
Virus excretion upon challenge with virulent PRV 
Virus excreted after challenge with virulent PRV was 
determined by the method described by VannIer et al ~ 
Briefly, nasal swabs were taken dally from individual pigs 
from before challenge to 12 days postchallenge The 
swabs were weighed before and after sampling and 
soaked in 2 ml of culture medium and stored at - 70°C 
for a maxtmum of 14 days Samples of 100 #1 of these 
culture media were taken and the numbers of plaque- 
forming units were determined The means ( + s e m ) were 
calculated of the 10-log of TCIDso on PD 5 cells per gram 
of mucus 
Statistical analysis 
Analysis of samples was performed by standardized 
tests and criteria for vahdlty have been described 
before 1° Student's t test was carried out to analyse 
stattsttcal significance of the results and p>005 was 
considered to be significant 
RESULTS 
Effect of SLP/S/W on the antibody response against 
iFlu3 in pigs 
In five independent experiments, groups of pigs were 
immunized twtce with a combination of three Influenza 
virus strains plus different adjuvants, and blood samples 
were taken 3 weeks after the second vaccination 
Antibody titres achieved by either SLP/S/W, S/W or 
SLP were compared with those of antigen alone or 
antigen plus O/W (Ftgure 1) 
In general, differences in titres against he three virus 
strains were seen between the indIvtdual experiments and 
responses against A/Swine were lower than those against 
the two other strains The mean factors of increase in 
responses to A/Swine, MRC-11 and X-79 observed varied 
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Figure 1 Effect of various adjuvants on the antibody response against 
influenza virus (a) A/Swine, (b) MRC-11 and (c) Xo79 m pigs after two 
vaccinat0ons Mean values for at least f ive animals are represented and 
vertical bars indicate s e m 
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Table 1 Comparmon of the effect of var)ous adjuvants on the anttbody responses to tFlu3 m pigs 
2-log ant=body t0tres at week 6 against 
A/Swine MRC-11 X-79 
Group Adjuvant n Mean s e m FOI S Mean s e m FOI S Mean s e m FOI S 
1 - 25 08 06 - a 27 08 - a 21 11 - a 
2 O/W 30 7 3 1 8 91 b 9 8 1 2 137 b 9 1 0 9 128 b 
3 SLP/S/W 35 9 1 1 6 315 c 11 6 1 1 478 c 10 6 0 8 362 c 
4 S/W 15 25 21 3 d 68 09 17 d 58 09 13 d 
5 SLP 5 24 09 3 d 56 1 1 7 e 66 05 23 d 
Results of the five independent experiments of Ftgure 1 were taken together Ptgs were =mmumzed intramuscularly wtth tFlu3 plus different adjuvants 
at weeks 0 and 3 and ant=body tttres were measured at week 6 by HI Mean value, s e m, factor of increase (FOI) and statmttcal mgnff=cance (S) of 
the results are represented Groups wh=ch are not statmttcally different (p >0 05) are mdtcated by the same letter 
Table 2 Comparison of the effect of various adjuvants on the anttbody responses against tPRV and hve PRV m p)gs 
2-log ant)body titres at week 6 against 
tPRV Dve PRV 
Group Adjuvant n Mean s e m FOI S n Mean s e m FOI S 
1 - 25 1 3 07 - a 20 75 1 1 - a 
2 O/W 30 6 9 1 5 49 c 20 10 3 1 4 7 b 
3 SLP/S/W 35 7 4 2 0 69 c 20 12 0 1 4 23 c 
4 S/W 15 3 2 1 3 4 b NT 
5 SLP 5 40 1 7 4 b 5 90 1 6 3 b 
NT, not tested 
Results of the five independent experiments of F~gures 2 and 3 were taken together Pigs were tmmumzed intramuscularly wtth tPRV or hve PRV plus 
different adjuvants at weeks 0 and 3 and anttbody tltres were measured at week 6 by SN Mean value, s e m, factor of increase (FOI) and stattsttcal 
stgmficance (S) of the results are represented Groups whtch are not statmttcally dtfferent (p>005) are mdtcated by the same letter 
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Ftgure 2 Effect of various adjuvants on the antibody response against 
)PRV m ptgs after two vacc)nattons Mean values for at least five ammals 
are represented and verttcal bars md)cate s e m 
from 3 to 23 for SLP, 3 to 17 for S/W, 91 to 137 for 
O/W, and 315 to 478 for SLP/S/W (Table 1) SLP/S/W 
proved to be significantly more effective than either SLP, 
S/W or O/W 
Stimulation of antibody responses to iPRV by SLP/S/W 
in pigs 
In five separate xperiments he effect of SLP/S/W on 
the antibody tltre against Inactivated PRV was compared 
with that of O/W, SLP or S/W, or with antigen alone 
(Ftoure 2) Both SLP and S/W induced mean fourfold 
Increases whereas O/W and SLP/S/W evoked increases 
of 49- and 69-fold, respectively (Table 2) S/W and 
SLP were significantly less effective than SLP/S/W in 
stimulating antibody responses against IPRV 
Effect of SLP/S/W on the antibody responses against 
live PRV in pigs 
The effect of SLP/S/W, SLP and O/W on the antibody 
response against live PRV was studied in four separate 
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Ftgure 3 Effect of various adjuvants on the antibody response against 
live PRV m pigs after two vacc)nat)ons Mean values for five ammals 
are represented and vertical bars indicate s e m 
experiments in pigs Animals were immunized twice with 
an Interval of 3 weeks and antibody tltres were measured 
3 weeks after the second vaccination (Ftgure 3) SLP/S/W 
and O/W significantly augmented the humoral response 
against live PRV with a factor of 23 and 7, respectively 
(Table 2) SLP/S/W was significantly more effective 
than O/W SLP alone Induced a slight, significant 
enhancement of antibody tltres 
Effect of SLP/S/W and O/W on virus excretion upon 
challenge 
Groups of five pigs were vaccinated twice with a time 
Interval of 3 weeks, 5 weeks after the second vaccination, 
they were challenged with virulent PRV Two out of 
five non-vaccinated control animals died shortly after 
challenge All animals that received live PRV vaccine 
with or without adjuvant survived the challenge 
Virus tltres in tonsillar swabs were monitored over 14 
consecutive days (Floure 4) Geometric means of the 
number of virus particles (TCIDso) per gram sample were 
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Table 3 Effect of O/W and SLP/S/W on the antibody response against tPPV m p~gs 
2-log antibody tltres against PPV at 
Week 0 Week 3 Week 6 
Group Adjuvant n Mean s e m S Mean s e m S mean s e m S 
1 O/W 5 <30 00  a 50  09  a 56  19 a 
2 SLP/S/W 5 <30 00  a 67  15 b 108 05  b 
Groups of five pigs were immuntzed intramuscularly with tPPV plus different adjuvants at weeks 0 and 3 AnUbody tltres were measured at week 0, 
3 and 6 by serum neutrahzatlon Mean value, s e m and statisttcal mgnfflcance (S) of the results are represented Groups which are not statlsUcally 
different (p>005)  are indicated by the same letter 
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Ftgure 4 Virus excretton by vaccinated and non-vaccinated pigs at 
different Ume intervals after challenge with wrulent PRV Mean btres of 
wrus m nasal flutd of unvaccinated pigs (O), ammals vaccinated twice 
wtth hve PRV wtthout adjuvant (0), hve PRV+O/W (A) or hve 
PRV + SLP/S/W (111) 
calculated The surviving unvaccinated animals excreted 
large amounts of virus during the time period from 1 to 
10 days after challenge Tltres higher than 105 virus 
particles per gram of sample were detected over a period 
of 6 days (days 1-7 after challenge) and virus excretion 
lasted for 10 days Animals that received antigen without 
adjuvant also excreted high amounts of PRV during the 
first 5 days but no significant excretion could be observed 
beyond day 7 postchallenge Immumzatlon of animals 
with live PRV plus adjuvant sagmficantly reduced wrus 
excretion Animals immunized with PRV plus O/W 
excreted over 4 consecutive days 104-105 TCIDso g-1 
whale those injected with SLP/S/W excreted about 104 
TCIDso of virus for only 1 day 
Areas under the curves (AUCs) and above the 
background values (I e 102 TCIDso g- 1) were calculated 
by integration and that of the group of control animals 
was considered to be 100% Vaccination of animals with 
anngen alone reduced the AUC to 57% Vaccination 
with O/W and SLP/S/W resulted an AUCs of 40 and 
36%, respectively 
Adjuvant acUvlty of SLP/S/W and O/W for the antibody 
response against iPPV 
Groups of pigs were lmmumzed twice with IPPV plus 
either SLP/S/W or O/W as adjuvant and antibody ntres 
were measured at different time intervals (Table 3) Before 
immunization, o antibodies were detected After the first 
rejection, significant antibody tatres in serum were 
observed and both adjuvants appeared to be equally 
effective Responses increased upon the second injection 
with vaccine and SLP/S/W evoked a significantly higher 
tltre than O/W 
DISCUSSION 
In the hterature, many adjuvants have been described 
but most data have been obtained from studies in 
laboratory animals Efficacy of these experimental 
adjuvants in target animals is often disappointing In this 
paper we described the adjuvant activity of a novel 
formulation in the target animal species, a e pigs It is 
the outcome of an extensive research programme on 
non-mineral o11 adjuvants for veterinary purposes which 
included the screening of a large number of different 
compounds and formulations in mace or guinea-pigs and 
subsequent testmg of promising substances m target 
animal species In laboratory animals, several experi- 
mental adjuvants displayed distinct activity with the 
different ypes of antigens tested and only those which 
exhibited strong overall activity were tested in target 
species Among several others, an experimental formulation 
comprising a synthetic polysucrose derlvatazed with 
sulfate and hpld groups and incorporated into a 
squalane-an-water mulsion (SLP/S/W) appeared to 
exert strong adjuvantlcaty against a protein, a hapten 
carrier, and two viral antigens 1° Subsequent testing in 
pigs revealed that this SLP/S/W was sagmficantly more 
effective than several other experimental formulations 
(data not shown) As reported here, it enhanced antibody 
responses against three inactivated Influenza viruses, 
inactivated and live PRV, and against inactivated PPV 
Relative to negative controls which received antigen 
without adjuvant, anti-influenza ntibody tltres were 
increased 315- to 478-fold Humoral responses against 
1PRV and lave PRV were increased 69- and 23-fold, 
respectively As compared with the commercially applied 
O/W adjuvant, SLP/S/W was about three- to fourfold 
more effecnve an stimulating responses against he three 
influenza virus strains tested, hve PRV and aPPV, and 
equally effective in enhancing responses against IPRV 
The two constituent substances SLP and S/W also 
augmented responses against he viral antigens but the 
combination thereof demonstrated synergistic activity 
Similar beneficial interaction has been observed in mice 
and guinea-pigs 1° In principle, adjuvants are used to 
compensate for lack of potency of lnacnvated antigens 
as compared with their live counterparts Experiments 
with inactivated and live PRV revealed that ~mmune 
responses against both types of anngens can be enhanced 
upon addlnon of an adjuvant The stlmulatory effect of 
adjuvants on the immunity induced by live antigens has 
been reported previously 11 12 and has resulted an 
improved vaccines against Aujeszky disease Considerable 
differences were seen an levels of antl-PRV antibody 
responses against either reactivated or hve PRV Live 
PRV vaccine without adjuvant evoked anttbody levels 
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that were comparable with those obtained by 1PRV plus 
adjuvant The possibility of increasing responses against 
live PRV by an adjuvant suggests that the immune 
system may not always react maximally to a live virus 
antigen 
Increased antibody tltres against live PRV upon 
vaccination corresponded closely to decreased titres of 
virus in nasal fluid at different intervals after challenge 
with virulent PRV A comparable, inverse relationship 
between humoral response and protection against virus 
excretion has been described by other investigators TM 13 
The role of circulating antibodies In protection against 
virus excretion can be deduced from investigation with 
inactivated antigen administered parenterally as this 
route of immunization is thought to be incapable of 
inducing significant levels of either cell-mediated or local 
immunity Intramuscular immunization of animals with 
purified protein gp50 of PRV evoked neutralizing 
antibodies in serum and reduced virus excretion upon 
challenge ~3 
Adjuvanticity of mineral oil emulsions is believed 
to be at least partially related to the persistence of 
oil components in the host, as emulsions of oil of 
either vegetable or animal origin are considerably less 
effective Additional active substances such as microbial 
glycohpids 14, synthetic block polymers of polyoxy- 
ethylene and polyoxypropylene with or without microbial 
products 15, avridme 16 or SLP, can compensate for low 
activity of the biodegradable oil emulsions 
The SLP/S/W adjuvant formulation was developed to 
replace mineral oil-based adjuvants, thereby reducing 
toxic side-effects of vaccination Vaccines at present used 
in pigs often contain 25-60% mineral oil Concentrations 
of SLP and squalane used in the experimental vaccines 
are considerably lower, namely 0 5 and 5 % respectively 
Furthermore, low toxicity and high biocompatlbihty of
squalane is expected since squalane is a normal 
constituent of animal tissue and as such is present In low 
concentrations in most animal species Next to squalene, 
it is the most common hydrocarbon i human sebum ~7 
As a consequence, plain emulsions of squalane are 
considered to be biodegradable and to be of low or no 
risk to consumers of food containing residues thereof 
Toxicological studies on squalane affirmed relative 
safety ~v Squalane has been used in cosmetics in high 
concentrations for more than 25 years and in pharma- 
ceuticals as a carrier for lipid drugs 1T The SLP used in 
this novel adjuvant formulation is a new chemical entity 
and besides lmmunostimulatory activity, biological 
effects are not known As it is built up of naturally 
occurring compounds, i e sucrose, fatty acids and sulfate, 
low toxicity of SLP and degradation products might be 
expected The sugar backbone, Ficoll-400, is a relatively 
inert copolymer of sucrose and epichlorohydrin and 
degradation of SLP m wvo is considered to include 
cleavage of lipid and sulfate-ester bonds rather than 
breakdown of the polymer Such a degradation will yield 
fatty acids, sulfate and polysucrose Taking into account 
(1) low doses of active components, (2) blocompatlblhty 
of squalane, (3) chemical composition and the most likely 
route of degradation of SLP, and (4) very low absorption 
rate of a polysucrose analogue with a 25-fold lower 
molecular weight by the gastrointestinal tract 18'~9, 
SLP/S/W is thought o be of low risk to the consumers 
of food made from animals treated with this adjuvant 
In summary, the novel SLP/S/W is an effective 
adjuvant for humoral responses against influenza virus 
strains A/Swine, MRC-11 and X-79, for inactivated and 
live PRV and for 1PPV, and the two active components 
(i e SLP and S/W) interact synergistically Despite lower 
doses of active substances and blocompatlbihty of the oil 
component, it is more effective overall than the O/W 
adjuvant currently used As far as we know, this is the 
first time that a non-mineral oil adjuvant has been proven 
to have such a high efficacy in pigs and thus it is a 
potential candidate for use in porcine vaccines 
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